DermoSafe is proud to announce the closing of an agreement with a private investor for a seed round of more than half a million CHF, with a possible funding increase totaling more than 1 million CHF during the upcoming years.
“We are particularly happy to bring this new investor on board as he brings his medical expertise and experience as a medical doctor. He therefore has a full understanding of the value of DermoSafe’s concept and of what it brings to all stakeholders in the healthcare ecosystem” says Mr Philippe Held, CEO and Founder. “This is a major milestone achieved by DermoSafe and it will definitely help to reach our vision, mission and goals”.
Dermoscopy is a proven method to ensure early detection of skin tumors (such as melanoma), and all the dermatologists agree that it is an essential clinical exam to detect and allow early treatment of life-threatening tumors. Dermoscopy provides much better performance (sensitivity and specificity) versus naked eye, which is very often not enough for an early detection.
Source: DermoSafe